Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial

Table 1 Effect size for PANSS total change score: Paliperidone palmitate vs. placebo (95% CI)

Paliperidone Palmitate Treatment Group
	234 mg (n = 459-Day 4; n = 476-Day 8)	39 mg (n = 155)	156 mg (n = 161)	234 mg (n = 160)
Day 4*	0.10 (-0.08, 0.29)
Day 8*	0.19 (0.01, 0.37)
Day 22		0.27 (0.05, 0.50)	0.30 (0.08, 0.52)	0.41 (0.19, 0.63)
Day 36		0.28 (0.06, 0.50)	0.43 (0.21, 0.64)	0.40 (0.18, 0.62)

*All paliperidone palmitate dose groups received 234 mg on Day 1, and their assigned dose on Day 8.
Type of effect size is Cohen's d; p-value is from two-sided Z test.

ISSN: 1471-244X